https://www.selleckchem.com/pr....oducts/cyclophospham
46-3.61). The hazard ratio (HR) for 5-year EFS was 2.08 (95% CI 2.93-4.13) while the 5-year HR for OS was 2.44 (95% CI 1.46-4.08). Conclusion IDRF-positive neuroblastoma patients have a higher risk of incomplete surgical resection, surgical complications, and 5-year mortality and/or relapse. Our results affirm that IDRFs remain a useful prognostic tool for neuroblastoma patients both for short and long-term outcomes. Level of evidence II.Golgi staining allows for the analysis of neuronal arborisations and connection
Beğen
Yorum Yap
Paylaş
